Comparing the current results to its competitors, Puretech Health Plc reported Revenue decrease in the 4 quarter 2025 year on year by -3.5 %, despite the revenue increase by the most of its competitors of 12.5 %, recorded in the same quarter.
Puretech Health Plc, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 169.28 %
Puretech Health Plc's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes major pharmaceutical and biotechnology companies, academic institutions, government agencies, and both public and private research institutions. Its competition encompasses companies with approved therapeutics for its target indications, as well as existing and emerging therapies. In idiopathic pulmonary fibrosis (IPF), approved drugs include pirfenidone (Esbriet) marketed by Roche, nintedanib (Ofev) and nerandomilast (Jascayd) marketed by Boehringer Ingelheim. In immuno-oncology (IO) treatments, competitors include CTLA-4 and PD-1/PD-L1 therapies such as Yervoy and Opdivo by Bristol-Myers Squibb (BMS), Keytruda by Merck, Tecentriq by Genentech, and T cell engager immunotherapies like Blincyto by Amgen. Competitors identified in company filings include Amgen, BMS, Boehringer Ingelheim, Genentech, Merck, and Roche.
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Lantern Pharma Inc's business model focuses on leveraging artificial intelligence and machine learning to identify and repurpose existing drugs for the treatment of various diseases.
: { message: That model is currently overloaded with other requests. You can retry your request, or contact us through our help center at help.openai.com if the error persists. (Pleas
Innoviva Inc's business model revolves around the development and commercialization of pharmaceutical products. The company primarily focuses on creating strategic collaborations and partnerships with biopharmaceutical companies to advance innovative therapies. Innoviva generates revenue through royalty payments received based on the sales of its partnered products.
Sources:
Puretech Health Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Puretech Health Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
